Cargando…

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study

BACKGROUND: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC). METHODS: Inclusion criteria of the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triggiani, Luca, Alongi, Filippo, Buglione, Michela, Detti, Beatrice, Santoni, Riccardo, Bruni, Alessio, Maranzano, Ernesto, Lohr, Frank, D’Angelillo, Rolando, Magli, Alessandro, Bonetta, Alberto, Mazzola, Rosario, Pasinetti, Nadia, Francolini, Giulio, Ingrosso, Gianluca, Trippa, Fabio, Fersino, Sergio, Borghetti, Paolo, Ghirardelli, Paolo, Magrini, Stefano Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518848/ https://www.ncbi.nlm.nih.gov/pubmed/28449007 http://dx.doi.org/10.1038/bjc.2017.103

Ejemplares similares

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance
por: Triggiani, Luca, et al.
Publicado: (2021)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO)
por: Mazzeo, Ercole, et al.
Publicado: (2021)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy
por: Verzoni, Elena, et al.
Publicado: (2022)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique
por: Borghetti, Paolo, et al.
Publicado: (2016)

Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes
por: Barbera, F, et al.
Publicado: (2017)

Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
por: Francolini, Giulio, et al.
Publicado: (2022)

In reply to Simcock et al.
por: Magrini, Stefano Maria, et al.
Publicado: (2020)

Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis
por: Francolini, Giulio, et al.
Publicado: (2022)

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
por: Guerini, Andrea Emanuele, et al.
Publicado: (2019)

Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab
por: Guerini, Andrea Emanuele, et al.
Publicado: (2020)

Light and shadows of a new technique: is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?
por: Buglione, Michela, et al.
Publicado: (2018)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic
por: Magrini, Stefano Maria, et al.
Publicado: (2020)

Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review
por: Gaito, Simona, et al.
Publicado: (2023)

Two months of radiation oncology in the heart of Italian “red zone” during COVID-19 pandemic: paving a safe path over thin ice
por: Buglione, Michela, et al.
Publicado: (2020)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients
por: Guerini, Andrea Emanuele, et al.
Publicado: (2020)

RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment
por: Guerini, Andrea Emanuele, et al.
Publicado: (2022)

Oligoprogression in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2021)

Stereotactic radiotherapy for brain oligometastases
por: Lupattelli, Marco, et al.
Publicado: (2022)

COVID-19 and radiation induced pneumonitis: Overlapping clinical features of different diseases()
por: Ippolito, Edy, et al.
Publicado: (2020)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Lung Radiofrequency Ablation: Potential as a Therapy to Oligometastasis and Oligorecurrence
por: Hiraki, Takao, et al.
Publicado: (2012)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
por: Macagno, Alban, et al.
Publicado: (2022)

Can we prevent COVID-19 from causing victims among uninfected cancer patients?()
por: Ramella, Sara, et al.
Publicado: (2020)

Stereotactic radiotherapy for oligometastases in the lymph nodes
por: Pasqualetti, Francesco, et al.
Publicado: (2022)

MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer
por: Cuccia, Francesco, et al.
Publicado: (2021)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bgf4a3fgfd2pdhrvlp7q3ouahd